Mary DiBiase - 30 Jun 2022 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: Chief Operating Officer
Issuer ticker: XFOR
Reported as of: 30 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jul 2022, 16:56:49 UTC
Prior SEC filing: 27 Jun 2022
Next SEC filing: 19 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Derek M. Meisner, attorney-in-fact

Key filing fact

Mary DiBiase filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 01 Jul 2022.

Key facts

This page summarizes Mary DiBiase's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Jul 2022, 16:56.

Change

Previous filing in this sequence was filed on 27 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XFOR transaction

Common Stock

Sale

Transaction value
Shares: -1,578
Change %: -0.87%
Price
Shares after: 179,609
Date: 30 Jun 2022
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.

Footnote F2

The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $0.88 to $0.92, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F3

Of the shares of common stock reported, 170,338 shares represent unvested restricted stock units.